Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction on Friday, November 1st. The shares were sold at an average price of $8.59, for a total transaction of $85,900.00. Following the completion of the sale, the chief financial officer now directly owns 44,878 shares in the company, valued at $385,502.02. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Zynex Price Performance

ZYXI stock traded down $0.76 during mid-day trading on Monday, reaching $8.00. The company’s stock had a trading volume of 110,670 shares, compared to its average volume of 172,064. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The company’s 50 day moving average is $8.11 and its two-hundred day moving average is $9.04. Zynex, Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The stock has a market cap of $254.77 million, a PE ratio of 54.07 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 earnings per share. Equities research analysts expect that Zynex, Inc. will post 0.2 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC increased its stake in Zynex by 66.5% during the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after acquiring an additional 118,615 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Zynex by 68.7% during the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock worth $1,769,000 after purchasing an additional 77,300 shares during the period. LSV Asset Management increased its position in shares of Zynex by 45.1% during the 1st quarter. LSV Asset Management now owns 108,935 shares of the company’s stock worth $1,348,000 after purchasing an additional 33,840 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in Zynex by 22.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock valued at $1,179,000 after buying an additional 26,368 shares during the period. Finally, WINTON GROUP Ltd lifted its position in Zynex by 147.6% in the second quarter. WINTON GROUP Ltd now owns 36,841 shares of the company’s stock valued at $343,000 after buying an additional 21,960 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ZYXI shares. HC Wainwright raised their target price on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada reduced their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.